SSP
ELTX icon

Sixth Street Partners’s Elicio Therapeutics ELTX Stock Holding History

Sixth Street Partners’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Buy
+31,706
New +$318K ﹤0.01% 3403

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Sixth Street Partners's ELTX Position: Q2 2026 in Review

Sixth Street Partners opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 31,706 shares worth $124K. The stake represents ﹤0.01% of the portfolio and ranks #3403 among its holdings.

38 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Sixth Street Partners held 31,706 shares of Elicio Therapeutics worth $124K as of Q2 2026.
  • Elicio Therapeutics was a new Sixth Street Partners position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Sixth Street Partners's portfolio in Q2 2026, its #3403 holding.
  • 38 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Sixth Street Partners's 13F filing for Q2 2026, filed 14 Aug 2026.